Gild
Gilead Sciences is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative therapeutics for people with life-threatening diseases. The company focuses on three main therapeutic areas: virology, oncology, and inflammation, offering more than 25 medicines globally and running 58 clinical programs. Gilead is a leader in HIV treatment and prevention, including the first FDA-approved 6-month HIV prevention injection, and has expanded into cell therapy and autoimmune disease treatments through acquisitions. The company emphasizes health equity, corporate responsibility, and inclusion, partnering worldwide to improve access to care and address health disparities. With over 18,000 employees worldwide, Gilead combines pioneering science with social impact initiatives to improve global health and patient outcomes.
Gild
Gilead Sciences is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative therapeutics for people with life-threatening diseases. The company focuses on three main therapeutic areas: virology, oncology, and inflammation, offering more than 25 medicines globally and running 58 clinical programs. Gilead is a leader in HIV treatment and prevention, including the first FDA-approved 6-month HIV prevention injection, and has expanded into cell therapy and autoimmune disease treatments through acquisitions. The company emphasizes health equity, corporate responsibility, and inclusion, partnering worldwide to improve access to care and address health disparities. With over 18,000 employees worldwide, Gilead combines pioneering science with social impact initiatives to improve global health and patient outcomes.